JP4839209B2 - 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法 - Google Patents

改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法 Download PDF

Info

Publication number
JP4839209B2
JP4839209B2 JP2006508697A JP2006508697A JP4839209B2 JP 4839209 B2 JP4839209 B2 JP 4839209B2 JP 2006508697 A JP2006508697 A JP 2006508697A JP 2006508697 A JP2006508697 A JP 2006508697A JP 4839209 B2 JP4839209 B2 JP 4839209B2
Authority
JP
Japan
Prior art keywords
microorganism
nucleic acid
antigen
cells
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006508697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521376A (ja
JP2006521376A5 (enExample
Inventor
トーマス ダブリュー． ジュニア ダベンスキー，
ダーク ジー． ブロックステット，
キース バージャット，
ジョン イー． ハースト，
デービッド クック，
Original Assignee
アンザ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンザ セラピューティクス，インコーポレイテッド filed Critical アンザ セラピューティクス，インコーポレイテッド
Publication of JP2006521376A publication Critical patent/JP2006521376A/ja
Publication of JP2006521376A5 publication Critical patent/JP2006521376A5/ja
Application granted granted Critical
Publication of JP4839209B2 publication Critical patent/JP4839209B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006508697A 2003-02-06 2004-02-06 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法 Expired - Fee Related JP4839209B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US44605103P 2003-02-06 2003-02-06
US60/446,051 2003-02-06
US44915303P 2003-02-21 2003-02-21
US60/449,153 2003-02-21
US49008903P 2003-07-24 2003-07-24
US60/490,089 2003-07-24
US51186903P 2003-10-15 2003-10-15
US60/511,869 2003-10-15
US54151504P 2004-02-02 2004-02-02
US60/541,515 2004-02-02
PCT/US2004/003671 WO2004084936A2 (en) 2003-02-06 2004-02-06 Modified free-living microbes, vaccine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007026192A Division JP2007131639A (ja) 2003-02-06 2007-02-05 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2006521376A JP2006521376A (ja) 2006-09-21
JP2006521376A5 JP2006521376A5 (enExample) 2007-03-29
JP4839209B2 true JP4839209B2 (ja) 2011-12-21

Family

ID=33102553

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006508697A Expired - Fee Related JP4839209B2 (ja) 2003-02-06 2004-02-06 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
JP2007026192A Pending JP2007131639A (ja) 2003-02-06 2007-02-05 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007026192A Pending JP2007131639A (ja) 2003-02-06 2007-02-05 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法

Country Status (8)

Country Link
US (1) US7833775B2 (enExample)
EP (1) EP1592442A2 (enExample)
JP (2) JP4839209B2 (enExample)
KR (1) KR101173871B1 (enExample)
AU (2) AU2004224425B2 (enExample)
CA (1) CA2515298C (enExample)
MX (1) MXPA05008340A (enExample)
WO (1) WO2004084936A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP1670505B1 (en) * 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2005092372A2 (en) * 2004-02-06 2005-10-06 Cerus Corporation Modified bacillus anthracis vaccine compositions and methods of use thereof
DE102004013988A1 (de) * 2004-03-19 2005-10-13 Henkel Kgaa Der Faktor RecA aus Bacillus licheniformis und recA-inaktivierte Sicherheitsstämme für die biotechnologische Produktion
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
JP2009504787A (ja) * 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US7947268B2 (en) 2005-11-14 2011-05-24 University Of Maryland, Baltimore Salmonella based oral vaccines for anthrax
WO2007101262A2 (en) * 2006-02-28 2007-09-07 The Board Of Regents Of The University Of Texas System Attenuated francisella bacteria
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
JP5347135B2 (ja) 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP2021021A2 (en) * 2006-05-12 2009-02-11 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
US8926993B2 (en) * 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
CA2665568C (en) * 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
WO2009013018A2 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
EP2576791B8 (en) 2010-05-23 2016-12-21 Aduro BioTech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
WO2011159814A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
ES2656498T3 (es) * 2010-09-07 2018-02-27 Sigma-Aldrich Co. Llc Células para inmunoprecipitación de cromatina y procedimiento de fabricación de las mismas
SI2640842T1 (sl) 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
HK1205944A1 (en) 2012-03-12 2015-12-31 阿德瓦希斯公司 Suppressor cell function inhibition following listeria vaccine treatment
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP2017532328A (ja) 2014-10-14 2017-11-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌治療用の併用療法
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
AU2016247887A1 (en) 2015-04-13 2017-11-02 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
MA44378A (fr) 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
EA201890149A1 (ru) 2015-06-26 2018-07-31 Сирус Корпорейшн Композиции криопреципитатов и способы их получения
EP3364986B1 (en) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inactivated cryo-poor plasma and methods of use thereof
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
JP2020503512A (ja) 2016-12-23 2020-01-30 シーラス コーポレイション 化合物結合基材を使用して、試験およびスクリーニングするためのシステムおよび方法
WO2018161020A1 (en) 2017-03-03 2018-09-07 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US20200282037A1 (en) * 2017-06-16 2020-09-10 Nantbio, Inc. Bacterial vaccine
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR102867700B1 (ko) 2017-12-29 2025-10-01 세루스 코포레이션 생물학적 유체를 처리하기 위한 시스템 및 방법
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
WO2020028794A1 (en) * 2018-08-02 2020-02-06 The Johns Hopkins University Compositions comprising annexin v and hpv tumor antigen fusion polypeptides
EP3838915A4 (en) * 2018-08-02 2022-02-09 Suzhou Royaltech Med Co., Ltd Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof
MX2021015653A (es) 2019-06-22 2022-04-11 Cerus Corp Sistemas de tratamiento de fluidos biologicos.
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US20230123485A1 (en) * 2020-03-11 2023-04-20 Superbrewed Food, Inc. Microbial compositions and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022226319A1 (en) * 2021-04-23 2022-10-27 Wake Forest University Health Sciences Psoralen-inactivated neisseria gonorrhoeae vaccines and methods thereof
KR102717863B1 (ko) 2023-06-09 2024-10-16 지보건설 주식회사 지반 보강공법 및 그 공법에 적용되는 굴삭기 버킷

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545987A (en) * 1983-12-20 1985-10-08 Advanced Genetics Research Institute Psoralen inactivated double-stranded RNA viral vaccines
US4693981A (en) * 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
WO1999026476A1 (en) * 1997-11-20 1999-06-03 Cerus Corporation New psoralens for pathogen inactivation
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
JP2001508449A (ja) * 1997-01-06 2001-06-26 セラス コーポレイション 病原体不活化のための脆い化合物
JP2002500204A (ja) * 1998-01-06 2002-01-08 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
WO2002040046A1 (en) * 2000-11-16 2002-05-23 Akzo Nobel N.V. Salmonella vaccine

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136738A (en) * 1873-03-11 Improvement in combined oil-cans and torches
US77263A (en) * 1868-04-28 Henry w
US9194A (en) * 1852-08-17 Pile-cutting machineby
US4556556A (en) * 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4791062A (en) * 1985-02-28 1988-12-13 Diamond Scientific Co. FVR vaccine
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
DK189788D0 (da) * 1988-04-07 1988-04-07 Wolf Watz Hans Vaccine
IL92996A (en) * 1989-01-10 1996-06-18 Bisaccia Emil Photovoltaic compounds as drugs for the treatment of viral infections and a method for the production of vaccines
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5180819A (en) * 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
FR2686896B1 (fr) 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6150170A (en) * 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6177441B1 (en) * 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
CA2199731A1 (en) 1995-06-07 1996-12-19 Susan Wollowitz Treating red blood cell solutions with anti-viral agents
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU1152397A (en) 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
CA2241604C (en) * 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
US5843459A (en) * 1996-01-19 1998-12-01 Human Gene Therapy Research Institute Differential inactivation of nucleic acids by chemical modification
BR9708387A (pt) * 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
EP0808897A1 (en) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
WO1998001538A1 (en) * 1996-07-10 1998-01-15 Immunex Corporation Method of activating dendritic cells
GB9615022D0 (en) 1996-07-17 1996-09-04 Mini Agriculture & Fisheries Vaccine preparations
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
WO1998005795A1 (en) * 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19635676A1 (de) * 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
WO1998033386A1 (en) * 1997-01-31 1998-08-06 Vanderbilt University Method of delivering antigens for vaccination with a live vector
WO1999003976A2 (en) 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
DE19754938B4 (de) 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
US6143551A (en) 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
EP1064357A1 (en) 1998-03-20 2001-01-03 Ludwig Institute For Cancer Research Processes for improved presentation of antigens by dendritic cells
CA2347067C (en) * 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6254863B1 (en) * 1998-08-12 2001-07-03 Loma Linda University Non-virulent Porphyromonas gingivalis mutant
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
GB9918283D0 (en) 1999-08-03 1999-10-06 Int Centre Genetic Eng & Bio Hsv vaccines
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
DE19949594A1 (de) 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US20030077263A1 (en) 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
IL151942A0 (en) 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
CZ20023662A3 (cs) * 2000-05-04 2003-04-16 President And Fellows Of Harvard College Sloučeniny a způsoby léčení a prevence bakteriální infekce
US20020150588A1 (en) * 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
EP1334177B1 (en) * 2000-11-14 2005-01-26 Université Libre de Bruxelles Generation and use of dendritic cells
EP1365750A2 (en) * 2000-12-21 2003-12-03 Cerus Corporation Methods for inactivation of pathogens in biological materials
US6783765B2 (en) * 2001-03-23 2004-08-31 Council Of Scientific And Industrial Research Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process
AU2002249531A1 (en) * 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
EP1513924A4 (en) * 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
US20040009194A1 (en) 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
AU2002950473A0 (en) 2002-07-26 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Expression system
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
CA2542631A1 (en) 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2005067460A2 (en) 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
AU2004314347B2 (en) 2003-12-24 2011-05-19 Aduro Biotech, Inc. Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US20070031457A1 (en) * 2004-02-06 2007-02-08 Dubensky Thomas W Jr Modified Bacillus anthracis, vaccine compositions and methods of use thereof
WO2005092372A2 (en) 2004-02-06 2005-10-06 Cerus Corporation Modified bacillus anthracis vaccine compositions and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545987A (en) * 1983-12-20 1985-10-08 Advanced Genetics Research Institute Psoralen inactivated double-stranded RNA viral vaccines
US4693981A (en) * 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
JP2001508449A (ja) * 1997-01-06 2001-06-26 セラス コーポレイション 病原体不活化のための脆い化合物
WO1999026476A1 (en) * 1997-11-20 1999-06-03 Cerus Corporation New psoralens for pathogen inactivation
JP2002500204A (ja) * 1998-01-06 2002-01-08 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
WO2002040046A1 (en) * 2000-11-16 2002-05-23 Akzo Nobel N.V. Salmonella vaccine

Also Published As

Publication number Publication date
WO2004084936A8 (en) 2004-12-16
KR101173871B1 (ko) 2012-08-16
MXPA05008340A (es) 2006-03-13
JP2006521376A (ja) 2006-09-21
US7833775B2 (en) 2010-11-16
CA2515298C (en) 2014-04-08
EP1592442A2 (en) 2005-11-09
US20040197343A1 (en) 2004-10-07
KR20060008860A (ko) 2006-01-27
AU2010202434A1 (en) 2010-07-01
AU2004224425B2 (en) 2010-06-24
JP2007131639A (ja) 2007-05-31
CA2515298A1 (en) 2004-10-07
AU2004224425A1 (en) 2004-10-07
WO2004084936A2 (en) 2004-10-07
WO2004084936A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
JP4839209B2 (ja) 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US7927606B2 (en) Modified free-living microbes, vaccine compositions and methods of use thereof
JP2006521376A5 (enExample)
US7691393B2 (en) Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
EP2283112B1 (en) Compositions comprising prfa*mutant listeria and methods of use thereof
JP2007503846A5 (enExample)
CN1758923B (zh) 进入非吞噬细胞被衰减的利斯特氏菌、含有该利斯特氏菌的疫苗
HK1082187B (en) Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110906

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111003

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4839209

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees